RMC No. 108-2025: Updated VAT-Exempt Drug List for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, Tuberculosis, and High Cholesterol

RMC No. 108-2025 updates the FDA-endorsed VAT-exempt drug list for key illnesses, affecting pharmacies, healthcare firms, and corporate tax teams. Businesses selling, importing, prescribing, purchasing, reimbursing, or accounting for qualified medicines must immediately validate their product master files, invoices, VAT treatment, and reimbursement rules against the updated VAT-exempt drug list endorsed by the Food and […]

RMC No. 131-2024: Updated VAT-Exempt Medicine List for Cancer, Diabetes, and Mental Illness Products

RMC No. 131-2024 updates the VAT-exempt medicine list for cancer, diabetes, and mental illness products, with effectivity tied to FDA publication. Businesses selling, dispensing, importing, distributing, or accounting for qualified medicines must immediately check the latest FDA-published list of VAT-exempt medicines because the VAT exemption under the CREATE Act takes effect based on the FDAโ€™s […]

RMC No. 100-2024: FDA-Endorsed Updates to VAT-Exempt Medicines for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, and Tuberculosis

RMC No. 100-2024 publishes FDA updates to VAT-exempt medicines and confirms exemption applies from the FDA publication date of the updated list. Businesses selling, purchasing, prescribing, distributing, or accounting for covered medicines must immediately check whether their products are included in the updated FDA-endorsed list of VAT-exempt products, because VAT exemption under RMC No. 100-2024 […]

RMC No. 34-2024: FDA Updates to VAT-Exempt Medicines for Cancer, Hypertension, and Mental Illness Under TRAIN and CREATE

RMC No. 34-2024 confirms FDA updates to VAT-exempt medicines for cancer, hypertension, and mental illness, with effect from FDA publication. Businesses selling medicines for cancer, hypertension, and mental illness must immediately check the latest Food and Drug Administration updates to the VAT-exempt product list because VAT exemption takes effect on the date the FDA publishes […]

RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RMC No. 42-2023: VAT-Exempt Medicines List Updated for FDA-Endorsed Products Under TRAIN and CREATE

RMC No. 42-2023 confirms FDA-endorsed updates to VAT-exempt medicines and applies exemption from FDA publication of the updated list. Pharmacies, hospitals, clinics, drug distributors, importers, and accounting teams dealing with medicines for cancer, diabetes, kidney disease, mental illness, tuberculosis, high cholesterol, and hypertension should immediately verify whether their products are covered by the FDA-endorsed updates […]

RMC No. 4-2019: VAT Exemption for FDA-Listed Diabetes, High-Cholesterol, and Hypertension Drugs

RMC No. 4-2019 publishes the FDA list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs for pharmacy and healthcare VAT compliance. Pharmacies, hospitals, drug distributors, and VAT-registered sellers of medicine must treat the FDA-identified drugs for diabetes, high cholesterol, and hypertension as VAT-exempt once covered by the published FDA list. RMC No. 4-2019 matters because the […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]

RR No. 25-2018: VAT Exemption on Diabetes, High Cholesterol, and Hypertension Medicines Starting January 1, 2019

RR No. 25-2018 exempts FDA-listed diabetes, cholesterol, and hypertension medicines from VAT on local sale starting January 1, 2019. Starting January 1, 2019, businesses selling covered medicines for diabetes, high cholesterol, and hypertension must treat qualified sales as VAT-exempt, but only if the drug or medicine is included in the official VAT-exempt list identified and […]